Lyumjev Kwikpen (3ml Each) contains Insulin Lispro (100 units/mL), a rapid-acting insulin analog indicated for the management of hyperglycemia in patients with diabetes mellitus. Lyumjev Kwikpen is designed to improve postprandial glucose control by facilitating rapid absorption and onset of action, typically within 15 minutes of subcutaneous administration. This insulin analog mimics physiological insulin secretion more closely than regular human insulin, thereby enhancing glycemic control when used in conjunction with diet and exercise. The Kwikpen delivery system offers a prefilled, disposable, and easy-to-use option for subcutaneous injection, allowing precise dosing and improved patient adherence. Lyumjev is suitable for both type 1 and type 2 diabetes patients requiring prandial insulin supplementation. It should be administered shortly before meals or immediately after eating, as directed by a healthcare professional. Dose adjustments should be individualized based on blood glucose monitoring, carbohydrate intake, and physical activity levels. Common adverse effects include hypoglycemia, injection site reactions, and potential allergic responses. Caution is advised in patients with hypoglycemia unawareness or impaired renal or hepatic function. Proper storage and handling instructions must be followed to maintain insulin potency. Lyumjev Kwikpen is a valuable option for optimizing glycemic control in diabetes management.